Model Developed to Predict Postoperative Opioid Use After Gynecologic Surgery
Researchers developed a predictive tool and an online calculator to potentially mitigate excessive postoperative opioid use in women undergoing gynecologic procedures.
Researchers developed a predictive tool and an online calculator to potentially mitigate excessive postoperative opioid use in women undergoing gynecologic procedures.
Researchers found that 18% of patients with advanced ovarian cancer remained disease-free for at least 10 years after receiving chemotherapy and were likely cured.
Researchers in Denmark sought to determine whether in utero exposure to maternal cancer increased risks of overall mortality, somatic diagnoses, and psychiatric diagnoses.
A systematic review sought to identify the survivorship issues important to survivors of gynecologic cancers.
Researchers analyzed data from more than 1 million women to determine if screening intervals could be safely extended with negative human papillomavirus tests compared with negative cytology screen results.
Many patients with advanced ovarian cancer may be eligible for first-line maintenance with a PARP inhibitor, research suggests.
A randomized study sought to determine the effect of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy on HRQOL for patients with advanced ovarian cancer.
The accelerated approval was based on data from two phase 2 trials: the ROAR basket study and the NCI-MATCH Subprotocol H study.
There was no significant difference in survival outcomes with trabectedin or physician’s choice of chemotherapy.
Researchers described distinct anxiety profiles and identified clinical characteristics of each one.